Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 3/20 | 0.67 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.67 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.67 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.67 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.67 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.67 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.67 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.67 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.67 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | OSBP | P22059 | 1/20 | 0.59 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28514223 | 1.00 | EPHA2 (0.67) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| SCHEMBL1954584 | 0.91 | EPHA2 (0.66) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| SCHEMBL31001156 | 0.88 | EPHA2 (0.52) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| SCHEMBL11785013 | 0.88 | OSBP (0.75) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| SCHEMBL11524136 | 0.88 | OSBP (0.75) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| SCHEMBL11571094 | 0.88 | OSBP (0.75) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| SCHEMBL28731645 | 0.88 | OSBP (0.75) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| SCHEMBL30526156 | 0.88 | GPBAR1 (0.71) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| SCHEMBL19866272 | 0.88 | CYP2D6 (0.71) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 | |
| SCHEMBL14676689 | 0.88 | CYP2D6 (0.71) | EPHA2GPBAR1HSD17B10TDP1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267139-A1 | ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN PICK DISEASE, TYPE C, IN PATIENTS WITH ER TYPE MISSENSE MUTATIONS | Zevra Denmark A/S (DK) | 2023-11-01 | — | — | EP | claimed |
| WO-2022136640-A1 | ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN PICK DISEASE, TYPE C, IN PATIENTS WITH ER TYPE MISSENSE MUTATIONS | ORPHAZYME A/S (DK) | 2022-06-30 | — | — | WO | claimed |
| EP-4608399-A1 | ARIMOCLOMOL COMPOSITIONS FOR USE IN TREATING NIEMANN PICK DISEASE TYPE C (NPC) | Zevra Denmark A/S (DK) | 2025-09-03 | — | — | EP | disclosed |
| US-20240115558-A1 | ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN PICK DISEASE, TYPE C, IN PATIENTS WITH ER TYPE MISSENSE MUTATIONS | KEMPHARM DENMARK A/S (DK) | 2024-04-11 | — | — | US | disclosed |
| EP-4267139-A1 | ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN PICK DISEASE, TYPE C, IN PATIENTS WITH ER TYPE MISSENSE MUTATIONS | Zevra Denmark A/S (DK) | 2023-11-01 | — | — | EP | disclosed |
| US-20230051742-A1 | TREATMENT OF LATE-ONSET NEURODEGENERATIVE DISEASES IN HETEROZYGOUS NPC1 GENE MUTATION CARRIERS | Intrabio Ltd. (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20220211687-A1 | USE OF ARIMOCLOMOL IN THE TREATMENT OF NIEMANN PICK DISEASE | Zevra Denmark A/S (DK) | 2022-07-07 | — | — | US | disclosed |
| WO-2022136640-A1 | ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN PICK DISEASE, TYPE C, IN PATIENTS WITH ER TYPE MISSENSE MUTATIONS | ORPHAZYME A/S (DK) | 2022-06-30 | — | — | WO | disclosed |
| US-11313866-B2 | Method of diagnosing and treating asphyxia | INFANDX AG (DE) | 2022-04-26 | — | — | US | disclosed |
| US-10514383-B2 | Diagnosis and treatment of neonatal encephalopathy | INFANDX AG (DE) | 2019-12-24 | — | — | US | disclosed |
| US-20180011111-A1 | Method of Diagnosing and Treating Asphyxia | INFANDX AG (DE) | 2018-01-11 | — | — | US | disclosed |
| US-9791459-B2 | Method of diagnosing and treating asphyxia | INFANDX AG (DE) | 2017-10-17 | — | — | US | disclosed |
| US-9085602-B1 | Facial amphiphiles and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140308687-A1 | Method and Use of Metabolites for the Diagnosis and Differentiation of Neonatal Encephalopathy | INFANDX AG (DE) | 2014-10-16 | — | — | US | disclosed |
| EP-2771696-A2 | METHOD AND USE OF METABOLITES FOR THE DIAGNOSIS AND DIFFERENTIATION OF NEONATAL ENCEPHALOPATHY | InfanDx AG (DE) | 2014-09-03 | — | — | EP | disclosed |
| WO-2013060788-A2 | METHOD AND USE OF METABOLITES FOR THE DIAGNOSIS AND DIFFERENTIATION OF NEONATAL ENCEPHALOPATHY | INFANDX AG (DE) | 2013-05-02 | — | — | WO | disclosed |
| US-20120136581-A1 | Method of Diagnosing Asphyxia | BIOCRATES LIFE SCIENCES AG (AT) | 2012-05-31 | — | — | US | disclosed |
| WO-2011080184-A1 | USE OF ENDOGENOUS METABOLITES FOR EARLY DIAGNOSING SEPSIS | BIOCRATES LIFE SCIENCES AG (AT) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115558-A1 | ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN PICK DISEASE, TYPE C, IN PATIENTS WITH ER TYPE MISSENSE MUTATIONS | NPC1, NPC1L1, CHERP | EPHA2 4564/4885GPBAR1 512/4885HSD17B10 2122/4885 |
| US-20220211687-A1 | USE OF ARIMOCLOMOL IN THE TREATMENT OF NIEMANN PICK DISEASE | NPC1, NPC1L1, GBA1 | EPHA2 4529/4885GPBAR1 2079/4885HSD17B10 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.